Rayzebio, Inc.

  • Market Cap: Small Cap
  • Industry: Biotechnology
  • ISIN: US75525N1072
USD
62.49
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2023)

FII

6.53%

Held by 32 FIIs

DII

43.23%

Held by 16 DIIs

Promoter

40.16%

How big is Rayzebio, Inc.?

22-Jun-2025

As of Feb 27, Rayzebio, Inc. has a market capitalization of 3,814.02 million, classifying it as a Small Cap company, with net sales of 0.00 million and a net profit of -53.34 million over the latest four quarters.

Market Cap: As of Feb 27, Rayzebio, Inc. has a market capitalization of 3,814.02 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Rayzebio, Inc. reported net sales of 0.00 million and a net profit of -53.34 million.<BR><BR>Balance Sheet Snapshot: As of Dec 22, the company reported shareholder's funds of 303.96 million and total assets of 324.78 million.

Read More

What does Rayzebio, Inc. do?

22-Jun-2025

Rayzebio, Inc. is a small-cap biotechnology company with a market cap of approximately $3.81 billion, currently reporting a net profit loss of $18 million as of September 2023. The company has no dividend yield and negative key financial metrics, including a debt equity ratio of -0.94 and a return on equity of -11.92%.

Overview:<BR>Rayzebio, Inc. operates in the biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Net Profit: -18 Million (Quarterly Results - Sep 2023)<BR>Market cap: USD 3,814.02 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.94<BR>Return on Equity: -11.92%<BR>Price to Book: 6.63<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 3,814 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.94

stock-summary
Return on Equity

-11.92%

stock-summary
Price to Book

6.63

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2023)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
176.5%
0%
176.5%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Rayzebio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-390.21%
EBIT to Interest (avg)
-39.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
95.26%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.63
EV to EBIT
-45.41
EV to EBITDA
-46.40
EV to Capital Employed
89.93
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-198.03%
ROE (Latest)
-11.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bearish
Bollinger Bands
Sideways
KST
Dow Theory
Bearish
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 25 Schemes (10.08%)

Foreign Institutions

Held by 32 Foreign Institutions (6.53%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Rayzebio, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -133.33% vs -326.09% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.60",
          "val2": "-38.90",
          "chgp": "-81.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-68.60",
          "val2": "-29.40",
          "chgp": "-133.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-70.60
-38.90
-81.49%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-68.60
-29.40
-133.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -133.33% vs -326.09% in Dec 2021

stock-summaryCompany CV
About Rayzebio, Inc. stock-summary
stock-summary
Rayzebio, Inc.
Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available